Life Science
Seminar
Bad Blood (feat.
organ-on-chip): Recreating the bone marrow in the lab to study acute
myeloid leukemia
Azmeer Sharipol, (RIT Biotechnology
’17)
Ph.D. Candidate and NCI
F99 Fellow, Biomedical Engineering
University of Rochester
Medical Center
Abstract: Acute myeloid leukemia
(AML) is an aggressive blood cancer that starts in the bone marrow.
Current therapies for AML result in a 5-year survival rate of ~30%,
highlighting the need for safer and more effective therapies. During AML,
leukemia cells over-accumulate in the bone marrow and change the function
of the surrounding cells to create a favorable environment for leukemia
cell survival. The dysregulation of the bone marrow causes loss of normal
hematopoiesis and is associated with the mortality and morbidity of AML.
Our research goal is to develop a clinically relevant 3D model of the
leukemic bone marrow microenvironment that can recapitulate the
phenotypes of AML. We utilize a combination of organ-on-chip,
microfluidics, and hydrogel technologies to successfully replicate the
bone marrow that can maintain blood stem cell function and mimic the
dysregulation due to leukemia
cells.
Intended Audience: All are Welcome!
To request an interpreter, please visit myaccess.rit.edu
END:VEVENT
END:VCALENDAR